| 1 |
35546143 | TOPK/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is involved in sorafenib resistance in RCC. | 2022 May 11 |
1 |
| 2 |
34076978 | Long noncoding RNA NEAT1 aggravates sorafenib-resistance in non-small cell lung cancer via regulating miRNA-335/c-Met. | 2021 Mar-Apr |
6 |
| 3 |
32504550 | Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer. | 2020 Aug |
1 |
| 4 |
33014851 | The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model. | 2020 |
1 |
| 5 |
30647407 | Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1. | 2019 Jan 15 |
4 |
| 6 |
29552141 | Synergistic antitumor activity of low-dose c-Met tyrosine kinase inhibitor and sorafenib on human non-small cell lung cancer cells. | 2018 Apr |
3 |
| 7 |
27849399 | New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails? | 2017 Jan |
1 |
| 8 |
28164434 | Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells. | 2017 Mar |
7 |
| 9 |
26790028 | Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. | 2016 Apr |
5 |
| 10 |
27203677 | Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma. | 2016 Jun 21 |
1 |
| 11 |
27896243 | Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date. | 2016 |
1 |
| 12 |
25668362 | Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review. | 2015 |
1 |
| 13 |
25862849 | Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression. | 2015 Apr |
1 |
| 14 |
25895026 | Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma. | 2015 May 20 |
1 |
| 15 |
25057499 | Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways. | 2014 |
2 |
| 16 |
23552472 | Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma. | 2013 Apr 3 |
1 |
| 17 |
23680714 | Advanced unresectable hepatocellular carcinoma: new biologics as fresh ammunition or clues to disease understanding? | 2013 Jul |
1 |
| 18 |
24330766 | Effects of miR-193a and sorafenib on hepatocellular carcinoma cells. | 2013 Dec 13 |
1 |
| 19 |
21734462 | c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. | 2011 Sep 15 |
4 |
| 20 |
20432459 | Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells. | 2010 Aug |
1 |
| 21 |
19220580 | Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. | 2009 Aug |
4 |